Harold Bernstein

President, Research & Development & Chief Medical Officer at Maze Therapeutics

Dr. Bernstein brings more than three decades of experience in basic scientific research, translational medicine, and clinical development both in industry and academia. In his current role at Maze, he is shaping and contributing to the creative strategy and thorough scientific process aimed at delivering new, genetic-based medicines. Before joining Maze, Dr. Bernstein was Senior Vice President, Chief Medical Officer, and Head of Global Clinical Development at BioMarin. Prior to that, he served as Head of Translational Medicine and Vice President of Global Medicines Development and Medical Affairs at Vertex and held roles of increasing responsibility at Merck and Co, including Head of Early Development for Cardiometabolic Diseases. He was a Professor of Pediatrics and a senior investigator at the Cardiovascular Research Institute and the Broad Center of Regeneration Medicine and Stem Cell Research at the University of California, San Francisco (UCSF). He also served as an attending physician at UCSF Benioff Children's Hospital in Pediatric Cardiology, and at the Mount Sinai Kravis Children’s Hospital in Cardiovascular Genetics. Currently, Dr. Bernstein holds an appointment as an Adjunct Professor of Pediatrics and the Mindich Child Health and Development Institute at the Icahn School of Medicine at Mount Sinai. He studied biomedical science, human genetics, and medicine at the Mount Sinai School of Medicine, earning MPhil, Ph.D., and MD degrees. He completed a pediatric residency, cardiology fellowship, and postdoctoral fellowship at UCSF and earned an undergraduate degree in biological sciences from Harvard College.


  • President, Research & Development & Chief Medical Officer

    Current role

View in org chart